

Special Issue

Optimizing Antibiotic Treatment: Pharmacokinetics and Clinical Trials

Message from the Guest Editors

For the success of an anti-infective therapy as well as the prevention of resistance development, the correct dosage is decisive, in addition to the choice of antibiotic and the duration of therapy. The pharmacological concept of therapy with antibiotics is based on the fact that a sufficient and adequate antibacterial effect is achieved at the site of the bacterial infection.

Distribution as a pharmacokinetic process depends on the pharmacological properties of the substances but also on physiological conditions. In this Special Issue on “Optimizing Antibiotic Treatment: Pharmacokinetics and Clinical Trials”, the progress made in optimizing antibiotic therapy from a pharmacokinetic perspective and the effects in different clinical areas will be published. The issue welcomes different types of submission, such as original research papers, short communications, reviews, case reports, and perspectives.

Guest Editors

Dr. Philipp Simon

Department of Anaesthesiology and Intensive Care Medicine,
University of Leipzig Medical Centre, Leipzig, Germany

Dr. David P. Nicolau

Center for Anti-Infective Research & Development Hartford Hospital,
80 Seymour Street, Hartford, CT 06102, USA

Deadline for manuscript submissions

closed (31 December 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/54577

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)